



Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015

May 12, 2015

Live Audio Webcast Will be on May 21, 2015

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will host an Analyst and Investor Day at the New York Palace Hotel in New York City on Thursday May 21, 2015 from 12:00 p.m. to 3:30 p.m. ET (9:00 a.m. to 12:30 p.m. PT).

Presenters will include:

- Kevin Gorman, President and Chief Executive Officer
- Timothy Coughlin, Chief Financial Officer
- Christopher O'Brien, Chief Medical Officer
- Kyle Gano, Chief Business Development Officer
- Dimitri Grigoriadis, Chief Research Officer
- Sylvia Hannaman, Director of Market Research and Planning
- Dr. Bruce Carr, MD, Professor of Obstetrics and Gynecology at UT Southwestern Medical Center
- Dr. Stewart Factor, Professor of Neurology Director, Emory Comprehensive Parkinson's Disease Center and the Movement Disorders Program
- Dr. Karen Lin Su, Medical Director Cares Foundation

To attend the live event at the New York Palace Hotel, please contact Neurocrine investor relations at ir@neurocrine.com.

To access the webcast on May 21, go to the homepage on www.neurocrine.com and click on the Webcasts & Presentations box to access the link. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-host-analyst-and-investor-day-in-new-york-city-on-may-21-2015-300082056.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, (858) 617-7600